Clinical Trials Browser

INDUSTRY × Doxorubicin × Breast × Clear all

NCT07441460 2026-03-02

A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer

Phase 3 Not yet recruiting

Resectable HER2-positive Breast Cancer

NCT05113251 2026-02-23

Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer

Phase 3 Active not recruiting

Breast Neoplasms

NCT04024462 2026-02-20

A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer

Phase 3 Completed

200 enrolled 16 charts

HER2-positive Early Breast Cancer

NCT06829199 2026-02-19

MK-5890-003

Phase 2 Withdrawn

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06112379 2025-12-17

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

Phase 3 Active not recruiting

Breast Neoplasms

NCT01358877 2025-11-28

APHINITY

Phase 3 Completed

4,804 enrolled 45 charts 1 FDA

Breast Neoplasms

NCT03725059 2025-07-11

KEYNOTE-756

Phase 3 Active not recruiting

Breast Neoplasms

NCT03554109 2025-02-21

TNBC

Phase 2 Withdrawn

Triple Negative Breast Neoplasms

NCT03678883 2024-11-07

9-ING-41 in Patients with Advanced Cancers

Phase 2 Active not recruiting

BreastCNSGastrointestinalGenitourinaryLymphoidOther hematologic neoplasmSarcomaThoracic

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

NCT03726879 2024-11-05

IMpassion050

Phase 3 Completed

454 enrolled 28 charts

Breast Neoplasms

NCT03493854 2024-06-26

FeDeriCa

Phase 3 Completed

500 enrolled 28 charts 2 FDA

Breast Neoplasms

NCT05207514 2024-05-17

Compare the Efficacy and the Safety of Taxotere and Nanoxel M as Neoadjuvant Chemotherapy in Breast Cancer

Phase 3 Terminated

Breast Neoplasms

NCT00712881 2024-02-23

Combination Therapy With MYOCET® (Doxorubicin HCL Liposome for Injection) in Participants With HER2-Positive Breast Cancer

Phase 2 Completed

126 enrolled 16 charts

Breast Neoplasms

NCT03197935 2023-10-26

IMpassion031

Phase 3 Completed

333 enrolled 18 charts

Triple Negative Breast Neoplasms

NCT04584112 2023-03-15

A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer

Phase 1 Completed

Triple Negative Breast Neoplasms

NCT05622058 2023-02-27

A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer

Phase 1 Terminated

Alopecia, Breast Neoplasms, Neutropenia

NCT02419742 2022-10-12

Safety and Efficacy of Trastuzumab as Part of Breast Cancer Treatment Regimen

Phase 4 Completed

110 enrolled 10 charts

Breast Neoplasms

NCT02076620 2022-04-04

L19TNFα in Combination With Doxorubicin in Patients With Advanced Solid Tumours

Phase 1 Completed

Breast Neoplasms, Sarcoma

NCT01220128 2021-05-25

INDUCT

Phase 2 Terminated

66 enrolled 40 charts

Breast Neoplasms

NCT02032277 2021-01-20

A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer

Phase 3 Completed

Neoplasms, Triple Negative Breast Neoplasms

NCT01940497 2020-11-03

SCHEARLY

Phase 3 Completed

240 enrolled 14 charts

Breast Neoplasms

NCT01697293 2020-09-24

PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer

Phase 1/2 Terminated

Breast Neoplasms

NCT02622074 2020-09-10

KEYNOTE 173

Phase 1 Completed

60 enrolled 26 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT04301739 2020-03-12

to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC)

Phase 3 Not yet recruiting

Triple Negative Breast Neoplasms

NCT02605915 2020-02-05

Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer

Phase 1 Completed

Breast Neoplasms

NCT00394251 2019-11-25

Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer

Phase 2 Completed

197 enrolled 23 charts

Breast Neoplasms

NCT01964391 2019-04-02

A Study of Participant Satisfaction and Safety With Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer

Phase 3 Completed

Breast Neoplasms

NCT00722293 2017-11-13

A Phase I, Open-label, Study of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid Tumors

Phase 1 Completed

BreastGynecologicSarcoma

Breast Neoplasms, Neoplasms, Ovarian Neoplasms, Sarcoma

NCT00550771 2017-06-07

Phase II Trial to Compare the Safety of Two Chemotherapy Plus Trastuzumab Regimens as Adjuvant Therapy for HER2-positive Breast Cancer (Study P05048)

Phase 2 Completed

181 enrolled 9 charts

Breast Neoplasms

NCT00021255 2016-11-15

Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer

Phase 3 Completed

3,222 enrolled 10 charts

Breast Neoplasms

NCT00455533 2016-02-24

Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer

Phase 2 Completed

384 enrolled 26 charts

Breast Neoplasms

NCT01815294 2015-12-04

A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer

Phase 1 Completed

BreastGynecologic

Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms

NCT02015676 2015-03-12

A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Metastatic or Locally Advanced Breast Cancer

Phase 1/2 Completed

69 enrolled 18 charts

Breast Neoplasms

NCT01998906 2014-10-28

A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Women With Locally Advanced Breast Cancer

Phase 3 Completed

330 enrolled 22 charts

Breast Neoplasms

NCT01131364 2014-02-25

Combination Therapy of F16IL2 and Doxorubicin in Solid Tumour Patients

Phase 1/2 Terminated

Breast Neoplasms

NCT00312208 2013-12-30

Docetaxel in Breast Cancer

Phase 3 Completed

3,299 enrolled 16 charts

Breast Neoplasms

NCT00446030 2012-06-26

Pilot Study of the Safety & Efficacy of Two Docetaxel-Based Regimens Plus Bevacizumab for the Adjuvant Treatment of Subjects With Node Positive or High Risk Node Negative Breast Cancer

Phase 2 Completed

127 enrolled 11 charts

Breast Neoplasms

NCT00149214 2012-03-21

Preoperative Treatment of Breast Cancer With Two Different Sequential Treatment Regimens

Phase 2 Completed

257 enrolled 15 charts

Breast Neoplasms

NCT00174655 2011-11-10

BIG 02/98 Docetaxel - Breast Cancer

Phase 3 Completed

Breast Neoplasms

NCT00688740 2011-02-16

TAX316

Phase 3 Completed

1,491 enrolled 12 charts

Breast Neoplasms

NCT00191789 2010-07-27

Neoadjuvant Sequential Administration of Two Gemcitabine Combinations in Operable Breast Cancer

Phase 2 Completed

65 enrolled 13 charts

Breast Neoplasms

NCT00294996 2009-03-31

Trial of Myocet in Metastatic Breast Cancer

Phase 3 Unknown

Breast Neoplasms

NCT00115414 2008-08-01

Same Day Dosing of Pegfilgrastim in Breast Cancer Patients Undergoing Chemotherapy (TAC)

Phase 2 Completed

Breast Neoplasms, Fever, Neutropenia

NCT00250874 2005-11-08

Myocet, Docetaxel & Trastuzumab as 1st Line Treatment of Patients With HER-2/Neu Positive Metastatic Breast Cancer

Phase 2 Unknown

Breast Neoplasms